Emerging therapies for respiratory syncytial virus (RSV), including ABRYSVO (RSVpreF), BEYFORTUS (nirsevimab), mRNA-1345, VAC 18193 (Ad26.RSV.preF), and others, are expected to drive growth in the RSV market in the coming years.
DelveInsight has released a new report titled “Respiratory Syncytial Virus – Market Insights, Epidemiology, and Market Forecast–2034”, offering a comprehensive overview of RSV, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Discover about the Respiratory syncytial virus market report @ https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Some of the key facts of the Respiratory syncytial virus Market Report:
According to DelveInsight’s patient-based model, the respiratory syncytial virus (RSV) market across the seven major markets (7MM) was valued at approximately USD 1.3 billion in 2023. RSV is a common respiratory virus affecting the nose, throat, lungs, and airways, with the highest incidence observed in children under five, followed by adults over 65, and the lowest rates in the 5–64 age group.
Until 2023, RSV management primarily relied on supportive care, such as hydration, nasal suctioning, and nutritional support, particularly for bronchiolitis. A major shift occurred in 2023 with the FDA approvals of the first RSV vaccines. AREXVY (RSVPreF3) and ABRYSVO (RSVPreF) were approved for adults aged 60 and older, with ABRYSVO also approved for use during pregnancy, making it the only RSV vaccine with that indication.
Preventive options further expanded in 2024 when BEYFORTUS (nirsevimab), a monoclonal antibody by AstraZeneca and Sanofi, received approval in Japan for preventing RSV-related lower respiratory tract infections in infants and young children. Already approved in the US and Europe, it is the only single-dose passive immunization available for a broad infant population.
Despite these advancements, RSV continues to pose a significant public health challenge, particularly for infants, young children, and older adults. Awareness among parents and families remains limited, highlighting the need for education, advocacy, and prevention strategies to improve vaccine uptake.
In 2023, the 7MM reported around 8.6 million new RSV cases, with the United States accounting for approximately 56% of cases. Nearly half of all RSV cases were in children under five.
Recent developments in RSV research include:
-
March 2025: AIM Vaccine Co., Ltd. received FDA approval to start clinical trials for its self-developed mRNA shingles vaccine, marking its second mRNA vaccine cleared by the FDA following its RSV mRNA vaccine.
-
March 2025: Clover Biopharmaceuticals obtained FDA IND approval and enrolled the first participant in a Phase I trial for SCB-1019, a bivalent, non-adjuvanted RSV PreF-Trimer subunit vaccine using Clover’s Trimer-Tag technology.
Key companies actively developing RSV therapies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising candidates include ABRYSVO (RSVpreF), BEYFORTUS (nirsevimab), mRNA-1345, VAC 18193 (Ad26.RSV.preF), and additional pipeline therapies poised to transform the RSV treatment landscape.
Respiratory syncytial virus Overview
Respiratory Syncytial Virus (RSV) belongs to the Orthopneumovirus genus, within the Pneumoviridae family and the Mononegavirales order. This genus includes human RSV, bovine RSV, and murine pneumonia virus. Human RSV is further classified into two main antigenic subtypes, A and B, which differ due to antigenic drift, duplications in the RSV-G gene, and broader genetic variations across the genome, including the RSV-F gene.
RSV spreads primarily through respiratory droplets released during coughing, sneezing, or close contact such as kissing, as well as via contaminated surfaces when hands touch the eyes, nose, or mouth. The virus can remain viable for several hours on hard surfaces like tables or crib rails, but survives for shorter periods on soft surfaces such as tissues or skin. Children are often exposed to RSV in settings like schools and daycare centers, and can transmit the infection to family members. RSV is extremely common, with almost all children infected by the age of two.
Respiratory syncytial virus Market Outlook
Despite increasing understanding of the pathogenesis and virology of respiratory syncytial virus (RSV), effective prevention options remain limited, and RSV continues to pose a substantial health burden. Until 2023, treatment was largely restricted to supportive care and prophylactic antibodies. The recent approval of vaccines such as AREXVY and ABRYSVO is expected to significantly reshape the RSV treatment landscape.
Traditionally, RSV management focused on alleviating respiratory symptoms—including wheezing, bronchitis, and shortness of breath—through the use of bronchodilators, antibiotics, and general supportive measures. The focus has recently shifted toward prevention, highlighted by the introduction of BEYFORTUS (nirsevimab), the first single-dose monoclonal antibody approved to protect a broad infant population—including children up to 24 months—through their first and second RSV seasons.
Despite these advances, there remains a substantial unmet need for safe, effective, and affordable RSV prevention and treatment options, such as antiviral therapies and long-acting monoclonal antibodies. Developing these solutions poses challenges, particularly in ensuring safety for vulnerable populations like infants and pregnant women. Ongoing innovation in vaccine development is crucial to reducing the global burden of RSV.
Discover how the Respiratory syncytial virus market is rising in the coming years @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Respiratory Syncytial Virus Marketed Drugs
-
ABRYSVO (RSVpreF): Pfizer
-
BEYFORTUS (nirsevimab): Sanofi/AstraZeneca
Respiratory syncytial virus Emerging Drugs
-
mRNA-1345: Moderna
-
VAC 18193 (Ad26.RSV.preF): Janssen
Scope of the Respiratory syncytial virus Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Respiratory syncytial virus Companies: Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others
-
Key Respiratory syncytial virus Therapies: ABRYSVO (RSVpreF), BEYFORTUS (nirsevimab), mRNA-1345, VAC 18193 (Ad26.RSV.preF), and others
-
Respiratory syncytial virus Therapeutic Assessment: Respiratory syncytial virus current marketed and Respiratory syncytial virus emerging therapies
-
Respiratory syncytial virus Market Dynamics: Respiratory syncytial virus market drivers and Respiratory syncytial virus market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Respiratory syncytial virus Unmet Needs, KOL’s views, Analyst’s views, Respiratory syncytial virus Market Access and Reimbursement
To know what’s more in our Respiratory syncytial virus report, visit https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key benefits of the Respiratory syncytial virus Market Report:
-
Respiratory syncytial virus market report covers a descriptive overview and comprehensive insight of the Respiratory syncytial virus Epidemiology and Respiratory syncytial virus market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
-
The Respiratory syncytial virus market report provides insights into the current and emerging therapies.
-
The Respiratory syncytial virus market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Respiratory syncytial virus market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Respiratory syncytial virus market.
Got queries? Click here to know more about the Respiratory syncytial virus market Landscape
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Respiratory syncytial virus Patient Share (%) Overview at a Glance
5. Respiratory syncytial virus Market Overview at a Glance
6. Respiratory syncytial virus Disease Background and Overview
7. Respiratory syncytial virus Epidemiology and Patient Population
8. Country-Specific Patient Population of Respiratory syncytial virus
9. Respiratory syncytial virus Current Treatment and Medical Practices
10. Unmet Needs
11. Respiratory syncytial virus Emerging Therapies
12. Respiratory syncytial virus Market Outlook
13. Country-Wise Respiratory syncytial virus Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Respiratory syncytial virus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Respiratory syncytial virus Market Outlook 2034
Related Reports:
Respiratory syncytial virus Pipeline Insights, DelveInsight
“Respiratory syncytial virus Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Respiratory syncytial virus market. A detailed picture of the Respiratory syncytial virus pipeline landscape is provided, which includes the disease overview and Respiratory syncytial virus treatment guidelines.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/